Hematologic Oncology Update Chronic Lymphocytic Leukemia — Proceedings from a Symposium Held in Partnership with the American Oncology Network
Dec 12, 2025
Dr. Kerry A. Rogers is an Associate Professor in the Division of Hematology at The Ohio State University, where she specializes in chronic lymphocytic leukemia (CLL). In the discussion, she outlines the latest treatment options, comparing continuous BTK inhibitors with venetoclax-based therapies. Dr. Rogers shares insights on emerging agents, including sonrotoclax and pirtobrutinib, and emphasizes the importance of MRD testing. She also presents case studies that highlight personalized treatment strategies depending on patient profiles and comorbidities.
AI Snips
Chapters
Transcript
Episode notes
Three Frontline Strategies Today
- There are three main frontline CLL strategies: continuous BTK inhibitors, venetoclax‑obinutuzumab, and BTK+venetoclax combinations.
- Fixed‑duration regimens reduce chronic toxicity, cost, and resistance risk but require venetoclax ramp‑up.
BTK Inhibitors Deliver Long Remissions
- Continuous covalent BTK inhibitors produce very long remissions and can normalize survival for many patients.
- Ibrutinib has the longest follow‑up but newer agents (acalabrutinib, zanubrutinib) appear similarly effective with fewer off‑target toxicities.
Avoid Chemoimmunotherapy
- Chemoimmunotherapy is no longer preferred given superior PFS with novel combinations.
- Consider limited‑duration BTK use to lower cardiovascular toxicity when appropriate.